Apyx Medical logo

Apyx MedicalNASDAQ: APYX

Profile

Sector:

Healthcare

Country:

United States

IPO:

02 January 2019

Next earnings report:

21 March 2025

Last dividends:

N/A

Next dividends:

N/A
$47.43 M
-92%vs. 3y high
35%vs. sector
-vs. 3y high
-vs. sector
-60%vs. 3y high
80%vs. sector
-92%vs. 3y high
25%vs. sector

Price

regular market | Fri, 15 Nov 2024 14:30:00 GMT
$1.26+$0.01(+0.80%)

Dividend

No data over the past 3 years
$11.49 M$12.99 M
$11.49 M-$4.70 M

Analysts recommendations

Institutional Ownership

APYX Latest News

Apyx Medical Corporation (APYX) Q3 2024 Earnings Call Transcript
seekingalpha.com08 November 2024 Sentiment: NEUTRAL

Apyx Medical Corporation (NASDAQ:APYX ) Q3 2024 Earnings Call Transcript November 8, 2024 8:00 AM ET Company Participants Jeremy Feffer - MD, LifeSci Advisors Stavros Vizirgianakis - Executive Chairman Charlie Goodwin - CEO Matt Hill - CFO Conference Call Participants Matthew O'Brien - Piper Sandler Matt Hewitt - Craig-Hallum Capital Group Sam Eiber - BTIG Ben Haynor - Lake Street Capital Markets Operator Ladies and gentlemen, good morning, and welcome to the Apyx Medical Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Apyx Medical (APYX) Reports Q3 Loss, Lags Revenue Estimates
zacks.com08 November 2024 Sentiment: NEUTRAL

Apyx Medical (APYX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.13 per share a year ago.

Apyx Medical Corporation Announces $7,000,000 Million Registered Direct Offering
globenewswire.com08 November 2024 Sentiment: POSITIVE

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical” or the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced it has entered into a definitive purchase agreement with Nantahala Capital for the purchase and sale in a registered direct offering of 3,000,000 shares of the Company's common stock at a purchase price of $1.18 per share and pre-funded warrants to purchase up to 2,934,690 shares of the Company's common stock at a purchase price of $1.179 per pre-funded warrant (which represents the per share offering price for common stock less the exercise price per share for each pre-funded warrant of $0.001). The gross proceeds to Apyx Medical from the offering were approximately $7,000,000, before deducting offering expenses payable by the Company. The offering closed on November 8, 2024.

Apyx Medical Corporation Reports Third Quarter 2024 Financial Results; Updates Full Year 2024 Financial Outlook and Introduces Full Year 2025 Financial Outlook
globenewswire.com08 November 2024 Sentiment: POSITIVE

CLEARWATER, Fla., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today reported the financial results for its third quarter ended September 30, 2024, updated its financial expectations for the full year ending December 31, 2024, and introduced its financial expectations for the full year ending December 31, 2025.

Apyx Medical Corporation to Release Third Quarter Of Fiscal Year 2024 Financial Results on November 8, 2024
globenewswire.com25 October 2024 Sentiment: POSITIVE

CLEARWATER, Fla., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency platform technology marketed and sold as Renuvion®, today announced that financial results for the third quarter of fiscal year 2024 will be released before the market opens on Friday, November 8th.

Apyx (APYX) Upgraded to Buy: Here's What You Should Know
zacks.com03 October 2024 Sentiment: POSITIVE

Apyx (APYX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Apyx Medical Corporation (APYX) Q2 2024 Earnings Call Transcript
seekingalpha.com11 August 2024 Sentiment: NEUTRAL

Apyx Medical Corporation (NASDAQ:APYX ) Q2 2024 Earnings Conference Call August 8, 2024 8:30 AM ET Company Participants Charles Goodwin - President, Chief Executive Officer & Director Matthew Hill - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Frank Takkinen - Lake Street Capitals George Sellers - Stephens Inc Operator Hello, and welcome, ladies and gentlemen, to the Second Quarter of Fiscal Year 2024 Earnings Conference Call for Apyx Medical Corporation. At this time all participants have been placed in a listen-only more.

Apyx Medical (APYX) Reports Q2 Loss, Lags Revenue Estimates
zacks.com08 August 2024 Sentiment: NEGATIVE

Apyx Medical (APYX) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.11 per share a year ago.

Apyx Medical Corporation Launches the "Renewing Lives" Give-Back Campaign Providing Treatments with Renuvion to Benefit Physical Appearance and Mental Health
prnewswire.com26 June 2024 Sentiment: POSITIVE

Renuvion is the only device FDA-cleared for contracting subcutaneous tissue  CLEARWATER, Fla. , June 26, 2024 /PRNewswire/ -- Apyx® Medical Corporation (NASDAQ: APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the launch of the "Renewing Lives" campaign, a nationwide, life-changing give-back program that will provide Renuvion treatments to people who can most benefit from this advanced medical technology.

Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript
Seeking Alpha21 March 2024 Sentiment: POSITIVE

Apyx Medical Corporation (APYX) Q4 2023 Earnings Call Transcript

What type of business is Apyx Medical?

Apyx Medical Corporation, an energy technology company, engages in the design, development, and manufacture of medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium plasma to cut, coagulate, and ablate soft tissue during open and minimally invasive surgical procedures. The company's Helium Plasma Technology products are marketed and sold under the Renuvion name in the cosmetic surgery market and under the J-Plasma name in the hospital surgical market. It also develops and manufactures various hand pieces for open and laparoscopic procedures; and OEM generators, as well as related accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.

What sector is Apyx Medical in?

Apyx Medical is in the Healthcare sector

What industry is Apyx Medical in?

Apyx Medical is in the Medical Devices industry

What country is Apyx Medical from?

Apyx Medical is headquartered in United States

When did Apyx Medical go public?

Apyx Medical initial public offering (IPO) was on 02 January 2019

What is Apyx Medical website?

https://apyxmedical.com

Is Apyx Medical in the S&P 500?

No, Apyx Medical is not included in the S&P 500 index

Is Apyx Medical in the NASDAQ 100?

No, Apyx Medical is not included in the NASDAQ 100 index

Is Apyx Medical in the Dow Jones?

No, Apyx Medical is not included in the Dow Jones index

When was Apyx Medical the previous earnings report?

No data

When does Apyx Medical earnings report?

The next expected earnings date for Apyx Medical is 21 March 2025